Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Patients with high-risk Stage II melanoma received Keytruda (pembrolizumab) after surgery to remove their original tumor.
Immunotherapy plus chemotherapy improved overall survival in people with persistent, recurrent or metastatic cervical cancer.
Imfinzi plus chemotherapy led to a modest but significant improvement in overall survival.
Keytruda plus chemotherapy reduced the risk of death by 27% in people with locally advanced or metastatic disease.
Opdivo plus relatlimab delayed disease progression compared with Opdivo alone.
The Food and Drug Administration recently approved the checkpoint inhibitor Keytruda (pembrolizumab).
Keytruda after kidney cancer surgery prolonged disease-free survival rates in patients at high risk for recurrence.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
The immunotherapy is now approved to treat tumors with a specific genetic mutation anywhere in the body.
Current and former smokers had better clinical outcomes with checkpoint inhibitors for lung cancer than nonsmokers.
This is the first immunotherapy approved for previously untreated triple-negative breast cancer that is likely to relapse.
Introducing errors in short-lived RNA causes tumors to present antigens on their cell surface, stimulating an immune response.
Sintilimab plus chemotherapy infused into a liver artery may offer the chance for a cure.
Tecentriq after surgery and chemotherapy delayed recurrence in people with Stage II or III non-small-cell lung cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.